Treatment practices for psoriasis and how they are changing - 11/01/21
Funding sources: None. |
|
Disclosure: Dr Fleischer is a consultant for Boehringer Ingelheim, Dermavant, Incyte, Qurient, SCM Lifescience, and Syneos and is an investigator for Galderma, Menlo, and Trevi. Dr Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GlaxoSmithKline/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation and is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Author Muddasani has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 84 - N° 2
P. 579-581 - février 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?